COMMUNIQUÉS West-GlobeNewswire

-
Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®
04/06/2025 -
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
04/06/2025 -
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
04/06/2025 -
Aveanna Healthcare Holdings Completes Acquisition of Thrive Skilled Pediatric Care
04/06/2025 -
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC
04/06/2025 -
The Joint Corp. Appoints Sandi Karrmann as Director
04/06/2025 -
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
04/06/2025 -
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
04/06/2025 -
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
04/06/2025 -
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
04/06/2025 -
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
04/06/2025 -
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
04/06/2025 -
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
04/06/2025 -
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
04/06/2025 -
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
04/06/2025 -
Revive Therapeutics Advances with Next-Generation Bucillamine Development
04/06/2025 -
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity
04/06/2025 -
Accumulus Synergy et Veeva Systems s’associent afin d’accélérer la transformation réglementaire et la connectivité
04/06/2025 -
TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors
04/06/2025
Pages